MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Schisantherin A

CAS No. : 58546-56-8

MCE 站：Schisantherin A

产品活性：Schisantherin A 是一种木脂素。Schisantherin A 通过 IκBα 降解来抑制 p65-NF-κB 易位进入细胞核。

研究领域：NF-κB

作用靶点：NF-κB

In Vitro: The concentrations of TNF-α and IL-6 in the supernatant of cells pretreated with 2.5 or 25 mg/L of Schisantherin A are significantly decreased compared to the LPS control group (p<0.05, p<0.01). The potential cytotoxicity of Schisantherin A is evaluated by the MTT assay after incubating cells for 24 h in the absence or presence of LPS, result shows cell viabilities are not affected by the cytokines at concentrations used (0.5, 2.5, 25 mg/L). RAW 264.7 murine macrophage cells are pre-incubated with Schisantherin A for 1 h and then stimulated with 1 mg/L LPS for 12 h. Both LPS and samples are untreated in control group. After the cell culture media are collected, nitrite and PGE₂ levels are determined, and Schisantherin A is found to reduce NO and PGE₂ production in a dose-dependent manner.

In Vivo: Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera, has been reported to possess varied beneficial pharmacological effects. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Pretreatment with Schisantherin A markedly ameliorates LPS-induced histopathologic changes and decreases the levels of TNF-α, IL-6 and IL-1β in the BALF. In addition, the phosphorylation of NF-κB p65, IκB-α, JNK, ERK and p38 induced by LPS are suppressed by Schisantherin A. The lung wet/dry weight ratio is evaluated at 7 h after the intranasal instillation of LPS. The results show that there are no differences between control group and Schisantherin A (40 mg/kg) group (p>0.05). LPS causes a significant increase in lung wet/dry weight ratio (p<0.01) compared with the control group. Schisantherin A dose-dependently decreases the lung wet/dry weight ratio (p<0.05) compared to those in the LPS group.

相关产品：Natural Product Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  NF-κB Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  Natural Product Library  |  Anti-Aging Compound Library  |  Antioxidants Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Pyroptosis Compound Library  |  Traditional Chinese Medicine Monomer Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Bortezomib  |  Pyrrolidinedithiocarbamate ammonium  |  JSH-23  |  Shikonin  |  Triptolide  |  Rocaglamide  |  Dihydroartemisinin  |  Baicalin  |  BAY 11-7085  |  Sulfasalazine  |  Betulinic acid  |  SN50  |  Parthenolide  |  (-)-DHMEQ  |  5-Aminosalicylic Acid  |  Caffeic acid phenethyl ester  |  Neferine  |  Tomatidine  |  QNZ  |  Withaferin A  |  Andrographolide  |  20(S)-Ginsenoside Rg3  |  Aristolochic acid A  |  B022  |  Maslinic acid  |  Ginsenoside Rb1  |  Lidocaine  |  Ethacrynic acid  |  Indole-3-carbinol  |  Mangiferin

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。